NASDAQ: TXG10x Genomics Inc Stock
$8.27-0.11 (-1.31%)
Updated Apr 30, 2025
TXG Price
$8.27
Fair Value Price
N/A
Market Cap
$1.01B
52 Week Low
$6.78
52 Week High
$28.25
P/E
-5.44x
P/B
1.42x
P/S
2.83x
PEG
N/A
Dividend Yield
N/A
Revenue
$610.79M
Earnings
-$182.63M
Gross Margin
67.9%
Operating Margin
-29.09%
Profit Margin
-29.9%
Debt to Equity
0.29
Operating Cash Flow
$7M
Beta
1.8
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
TXG Overview
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TXG's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
TXG
Ranked#40 of 45
Ranked#40 of 45
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $109.97 | A | |
| $26.03 | A | |
| $4.63 | B |
Be the first to know about important TXG news, forecast changes, insider trades & much more!
TXG News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TXG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TXG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TXG is good value based on its book value relative to its share price (1.42x), compared to the US Health Information Services industry average (3.52x)
P/B vs Industry Valuation
TXG is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TXG due diligence checks available for Premium users.
Valuation
TXG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.44x
Industry
40.3x
Market
29.18x
TXG price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.42x
Industry
3.52x
TXG is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TXG's financial health
Profit margin
Revenue
$165.0M
Net Income
-$49.0M
Profit Margin
-29.7%
TXG's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TXG's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$918.6M
Liabilities
$208.5M
Debt to equity
0.29
TXG's short-term assets ($584.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TXG's short-term assets ($584.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TXG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TXG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.7M
Investing
-$51.6M
Financing
$4.5M
TXG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TXG vs Health Information Service Stocks
10x Genomics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.